Human Adenovirus 14 is a species B adenovirus (subgroup B2) belonging to the genus *Mastadenovirus*. This non‑enveloped icosahedral virus with a linear double‑stranded DNA genome has gained attention for causing outbreaks of severe acute respiratory disease in otherwise healthy adults.
Virology and Entry Mechanisms
Adenovirus 14 virions are approximately 90 nm in diameter and feature a capsid made of hexon, penton base and fiber proteins. The fiber knob interacts with host cell receptors such as CD46 and desmoglein 2, allowing the virus to attach to respiratory epithelial cells. Following receptor‑mediated endocytosis and uncoating, the viral genome is transported to the nucleus where early genes hijack host replication machinery and a viral DNA polymerase replicates the genome. Late gene products assemble into new virions that are released upon cell lysis.
Clinical Impact and Emerging Outbreaks
Type 14 adenovirus, including the emergent variant 14a, is associated with acute febrile respiratory illness that can progress to severe pneumonia requiring hospitalization. Symptoms include high fever, cough, dyspnea and chest pain. Outbreaks have occurred in military training facilities, long‑term care homes and community settings, with cases reported in North America, Europe and Asia. In some outbreaks, adenovirus 14 has been linked to acute respiratory distress syndrome (ARDS) and death even in young adults. Transmission occurs through respiratory droplets and contaminated surfaces. Diagnosis relies on PCR assays, and management is supportive; no specific antiviral therapy is approved, though cidofovir may be considered in severe cases. There is no licensed vaccine for adenovirus 14 outside of the military adenovirus 4/7 vaccine, which does not cover this serotype. Human adenovirus 14 exemplifies how adenovirus serotypes can re‑emerge and cause significant respiratory disease, underscoring the need for surveillance and infection control in congregate environments. Related Terms: human adenovirus 7, human adenovirus 21, acute respiratory distress syndrome, CD46 receptor, emerging pathogen